Prescribing Cystadane

CYSTADANE is available exclusively through the specialty pharmacy Anovo (www.anovorx.com).

For patient home delivery:

  1. Download and fill out a CYSTADANE treatment form.
  2. Fax the form to 1-855-813-2039.

For inpatient orders:

Call 1-888-487-4703 and select option 2 to place a wholesale order for inpatient use.

Anovo will work with hospitals to ensure continuity of therapy when transitioning newly diagnosed patients from hospital to home settings.

The Anovo team will provide support every step of the way

  1. Benefit investigation and prior authorization support, if needed
  2. Shipping CYSTADANE to patient’s home
  3. Follow-up calls to promote adherence
cystadane anovo

For patients experiencing insurance changes, download resources to support your practice:

Letter of Appeal Template for CBS Deficiency
Open Letter of Appeal Template

CYSTADANE Financial Assistance Programs

Recordati Rare Diseases Inc., the distributor of CYSTADANE, is committed to reducing financial barriers regarding access to CYSTADANE:

Copay Assistance Program

Helps eligible patients with insurance copay and coinsurance costs for CYSTADANE. Offers a $0 copay for qualified commercially insured patients.

Patient Assistance Program

Helps eligible uninsured or underinsured patients get CYSTADANE.


Anovo will be able to determine whether your patients are eligible for these programs.

Questions? Call Anovo at 1-888-487-4703.
Spanish translation services are available.

Lowering homocysteine
concentrations with CYSTADANE

See the Clinical Data

Resources for your
patient

Download helpful patient resources

LEARN MORE

INDICATIONS AND USAGE

Cystadane is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations. Included within the category of homocystinuria are:

  • Cystathionine beta-synthase (CBS) deficiency
  • 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency
  • Cobalamin cofactor metabolism (cbl) defect

IMPORTANT SAFETY INFORMATION

  • Hypermethioninemia in Patients with CBS Deficiency: CYSTADANE may worsen elevated plasma methionine concentrations and cerebral edema has been reported. Monitor plasma methionine concentrations in patients with CBS deficiency. Keep plasma methionine concentrations below 1,000 micromol/L through dietary modification and, if necessary, a reduction of CYSTADANE dosage.
  • Most common adverse reactions (> 2%) are: nausea and gastrointestinal distress, based on physician survey.
  • To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See More

IMPORTANT SAFETY INFORMATION

  • Hypermethioninemia in Patients with CBS Deficiency: CYSTADANE may worsen elevated plasma methionine concentrations and cerebral edema has been reported. Monitor plasma methionine concentrations in patients with CBS deficiency. Keep plasma methionine concentrations below 1,000 micromol/L through dietary modification and, if necessary, a reduction of CYSTADANE dosage.
  • Most common adverse reactions (> 2%) are: nausea and gastrointestinal distress, based on physician survey.